Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
DPH2 CRISPR/Cas9 KO Plasmid (h): sc-409607
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- DPH2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the DPH2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: DPH2 Antibody (6E7): sc-101200
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DPH2 CRISPR/Cas9 KO Plasmid (h) | sc-409607 | 20 µg | $397.00 |
Overview
DPH2 encodes an essential enzyme in the diphthamide biosynthesis pathway that modifies a conserved histidine on eukaryotic translation elongation factor 2 (EEF2). This post-translational modification supports translation fidelity and influences cellular responses to ribosome-targeting stress, linking DPH2 activity to core protein synthesis control. Perturbation of diphthamide pathway components can alter proteostasis and stress signaling, making DPH2 a useful node for studying translational regulation mechanisms. Because EEF2 diphthamide is also a determinant of sensitivity to certain bacterial toxins, DPH2 provides a tractable entry point for investigating host–pathogen interactions and toxin biology in human cells.
DPH2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the DPH2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the DPH2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the DPH2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish DPH2 protein expression.
This CRISPR knockout system enables efficient generation of DPH2-deficient cell models for investigation of DPH2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting DPH2 exon(s) critical for DPH2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple DPH2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by DPH2 CRISPR/Cas9 KO Plasmid (h) and DPH2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the DPH2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by DPH2 HDR Plasmid (h) and DPH2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by DPH2 homology arms to support homology-directed repair at defined DPH2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.